OTC ORAL WOUND CLEANSERS WILL BE COVERED BY FDA
Executive Summary
OTC ORAL WOUND CLEANSERS WILL BE COVERED BY FDA in an upcoming tentative final monograph for oral anesthetic/analgesics, astringents, debriding agents, oral wound cleansers, and demulcent drug products. Carbamide peroxide, hydrogen peroxide, and sodium perborate monohydrate will be treated as debriding agents and oral wound cleansers, FDA said in a July 18 Federal Register notice regarding oral wound healing agents. The decision to combine debriding agents and oral wound cleansers into one therapeutic class followed from industry comments on the wound healing monograph. The comments "pointed out the similarities between oral wound cleansers and debriding agents and requested that the labeling for these ingredients be consistent between the two rulemakings," the agency explained. FDA further noted that combination products containing an oral wound cleanser and an antiseptic will be covered in another monograph. In the July 18 Federal Register notice, the agency said no information on efficacy was submitted to support continued use of four ingredient groups as oral wound healing agents. "Allantoin, carbamide peroxide in anhydrous glycerin, water soluble chlorophyllins, and hydrogen peroxide in aqueous solution are safe for use as oral wound healing, agents," the agency noted, "but there are inadequate data to establish general recognition of the effectiveness of these ingredients as oral wound healing agents." FDA defined oral wound healing agents as "aids in the healing of minor oral wounds by means other than cleansing and irrigating, or by serving as a protectant." The Federal Register notice sets a deadline of July 18, 1987 to relabel or reformulate products to remove the oral wound healing claim. "The agency is aware," FDA said, "that products containing some of the above ingredients have been on the OTC market and that these OTC drug products have had multiple claims. Purported oral wound healing agents must be removed from these OTC drug products or the product must be relabeled to exclude oral wound healing claims by the effective date of this final rule unless the product has an approved NDA." Although the OTC rule appeared in the July 18 Federal Register, it was approved for publication by FDA Com. Young and HHS Secty. Bowen on March 5. The four-month delay to Federal Register publication for a minor OTC rule exemplifies the wrapping up difficulties for the OTC Review.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth